Accéder au contenu
Merck

387A

Leukocyte Acid Phosphatase (TRAP) Kit

Kit formulated with all liquid reagents

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

UNSPSC Code:
12352106
NACRES:
NA.47
eCl@ss:
42010102
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

dilution

(for histology)

application(s)

hematology
histology

shipped in

wet ice

storage temp.

2-8°C

Quality Level

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Biochem/physiol Actions

Peripheral blood or bone marrow preparations are fixed to a microscope slide. The resulting film is incubated in a solution of Naphthol AS-BI phosphoric acid and freshly diazotized Fast Garnet GBC. Kit is used to demonstrate acid phosphatase and tartrate resistant acid phosphatase (TRAP) in blood, bone marrow and tissue touch preparations.

Composants de kit seuls

Réf. du produit
Description

  • Hematoxylin Solution, Gill No. 3 (kit only) 50 mL

Composants de kit également disponibles séparément

Réf. du produit
Description
FDS

  • 3863Acetate Solution, 2.5 M, pH 5.2 50 mLFDS

  • 915Citrate Solution, pH 3.6±0.1 (25 °C), 27 mM 50 mLFDS

  • 3872Fast Garnet GBC Base Solution 10 mLFDS

  • 3871Naphthol AS-BI Phosphoric Acid Solution 10 mLFDS

  • 914Sodium nitrite solution 10 mLFDS

  • 3873Tartrate Solution 10 mLFDS

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Carc. 1B - Eye Dam. 1 - Met. Corr. 1 - Skin Corr. 1B - STOT RE 2 Oral

target_organs

Kidney

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

L Wei et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 25(8), 2089-2096 (2014-05-09)
Recently, the use of the pharmacological agent strontium ranelate has come to prominence for the treatment of osteoporosis. While much investigation is focused on preventing disease progression, here we fabricate strontium-containing scaffolds and show that they enhance bone defect healing
Jihai Wang et al.
Frontiers in pharmacology, 9, 64-64 (2018-02-24)
Lipopolysaccharide (LPS) can induce bone loss by stimulating bone resorption. Natural compounds have great potential for the treatment of osteolytic bone diseases. Magnesium lithospermate B (MLB) plays an important role in protecting against oxidative damage and also has potential anti-inflammatory
Yu Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 47(6), 2291-2306 (2018-07-06)
Osteoporosis is a commonly occurring condition marked by a loss of bone density. Previous evidence has highlighted the roles played by microRNAs as potential treatment tools for the disease. At present, the influence of long non-coding RNAs (lncRNAs) on the
Yun Zhang et al.
Biological & pharmaceutical bulletin, 39(12), 2028-2035 (2016-12-03)
Osteolysis induced by chronic Gram-negative bacterial infection underlies many bone diseases such as osteomyelitis, septic arthritis, and periodontitis. Drugs that inhibit lipopolysaccharide (LPS)-induced osteolysis are critically needed for the prevention of bone destruction in infective bone diseases. In this study
Isabella Azario et al.
Scientific reports, 7(1), 9473-9473 (2017-08-27)
Umbilical cord blood (UCB) is a promising source of stem cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several genetic diseases that can be diagnosed at birth. Mucopolysaccharidosis type I (MPS-I) is a progressive multi-system disorder caused

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique